PMID 24248213
& Porter, C
Review Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH (2016) Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
For fatty liver disease without diabetes or obesity meeting treatment thresholds , NHS access to GLP-1 agonists is currently very limited
As litigation unfolds and regulatory clarity emerges, stakeholders will need to stay informed and adaptable to responsibly meet patient needs in this rapidly changing therapeutic space
Evidence was grouped by peptide agent and clinical domain, including tendon and ligament healing, cartilage and osteoarthritis, bone remodeling and fracture repair, wound healing, and postoperative recovery